Flumazenil for the Treatment of Refractory Hypersomnolence: Clinical Experience with 153 Patients | Zendy

Lynn Marie Trotti | Zendy; Prabhjyot Saini | Zendy; Catherine Koola | Zendy; Vincent LaBarbera | Zendy; Donald L. Bliwise | Zendy; David B. Rye | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Flumazenil for the Treatment of Refractory Hypersomnolence: Clinical Experience with 153 Patients

Author(s) -

Lynn Marie Trotti,

Prabhjyot Saini,

Catherine Koola,

Vincent LaBarbera,

Donald L. Bliwise,

David B. Rye

Publication year - 2016

Publication title -

journal of clinical sleep medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.529

H-Index - 92

eISSN - 1550-9397

pISSN - 1550-9389

DOI - 10.5664/jcsm.6196

Subject(s) - medicine , flumazenil , refractory (planetary science) , anesthesia , wakefulness , benzodiazepine , electroencephalography , psychiatry , physics , receptor , astrobiology

Patients with central disorders of hypersomnolence sometimes do not achieve satisfactory symptom control with currently available wake-promoting medications. Based on the finding that the cerebrospinal fluid from some patients with hypersomnolence demonstrates potentiation of gamma-aminobutyric acid (GABA)-A receptors in excess of that of controls, a finding that reverses with flumazenil, we initiated prescribing compounded flumazenil to carefully selected, treatment-refractory hypersomnolent patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research